Results 91 to 100 of about 3,645,426 (307)

Electroporation and Immunotherapy—Unleashing the Abscopal Effect

, 2022
SIMPLE SUMMARY: Electrochemotherapy and irreversible electroporation are primarily used for treating patients with cutaneous and subcutaneous tumors and pancreatic cancer, respectively.
Nolsoe, Christian, Adile Orhan, Raskov, Hans, Orhan, Adile, Hans Raskov, Justesen, Tobias Freyberg, Gögenur, Ismail, Tobias Freyberg Justesen, Ismail Gögenur, Christian Nolsoe   +9 more
core   +1 more source

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide

Journal for ImmunoTherapy of Cancer, 2016
Background Cancer vaccines aim at eliciting not only an immune response against specific tumor antigens, but also at enhancing a preexisting immunity against the tumor.
Michael Papamichail, Panagiotis Tzonis, Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Sonia A. Perez, Constantin N. Baxevanis   +5 more
doaj   +1 more source

Predictive and prognostic biomarkers of Bacillus Calmette‐Guérin therapy failure in bladder cancer patients: A systematic review

Molecular Oncology, EarlyView.
High‐risk bladder cancer is typically treated with Bacillus Calmette‐Guérin (BCG), but 30–40% of patients relapse. No FDA‐ or CE‐approved biomarkers currently predict or prognosticate BCG failure. We systematically reviewed the literature and identified 72 eligible studies, revealing several promising biomarkers associated with BCG treatment response ...
Rui Ribeiro‐Pereira, Ana Teixeira‐Marques, Rui Freitas, João A Carvalho, Sara Monteiro‐Reis, Giorgio I. Russo, Rui Henrique, Carmen Jerónimo   +7 more
wiley   +1 more source

Interactions between Dietary Micronutrients, Composition of the Microbiome and Efficacy of Immunotherapy in Cancer Patients

, 2022
The effectiveness of immunotherapy in cancer patients depends on the activity of the host’s immune system. The intestinal microbiome is a proven immune system modulator, which plays an important role in the development of many cancers and may ...
Paweł Krawczyk, Grenda, Anna, Milanowski, Janusz, Kalinka, Ewa, Frąk, Małgorzata, Krawczyk, Paweł, Małgorzata Frąk, Ewa Kalinka, Janusz Milanowski, Anna Grenda   +9 more
core   +1 more source

Extracellular matrix remodeling and immune reprogramming drive residual tumor progression of liver cancer after incomplete microwave ablation

Molecular Oncology, EarlyView.
Incomplete microwave ablation (iMWA) of liver cancer triggers a biphasic progression in residual tumors. At Day 3, the microenvironment is characterized by acute inflammatory responses and extracellular matrix (ECM) remodeling. By Day 14, a profound shift occurs toward oncogenic signal transduction and immunosuppression, marked by macrophage ...
Yu Liu, Yubei He, Nikolaus Berndt, Michael Mülleder, Kathrin Textoris‐Taube, Jing Guo, Matthias Stechele, Justus Ramtke, Shraga Nahum Goldberg, Lynn Jeanette Savic   +9 more
wiley   +1 more source

Immunotherapy of Ovarian Cancer with Particular Emphasis on the PD-1/PDL-1 as Target Points

, 2021
Ovarian cancer is one of the most fatal cancers in women worldwide. Cytoreductive surgery combined with platinum-based chemotherapy has been the current first-line treatment standard.
Mateusz Kozłowski, Sebastian Kwiatkowski, Aneta Cymbaluk-Płoska, Janina Świderska   +3 more
core   +1 more source

Cancer vaccine overcomes immune evasion of nasopharyngeal carcinoma by restoring MHC-I through transcriptional regulation of NLRC5

Journal of Translational Medicine
Background Nasopharyngeal carcinoma (NPC) is considered an immune-hot tumour. However, 30–80% of cases exhibit downregulation of antigen processing and presentation machinery (APM), enabling the evasion of host immunosurveillance.
Chai Phei Gan, Sau Yee Kok, Bernard Kok Bang Lee, Natasha Zulaziz, Sok Ching Cheong, Natalia Savelyeva, Kue Peng Lim   +6 more
doaj   +1 more source

Reprogramming tumor cells with LCOR mRNA nanotherapy to enhance immunotherapy

Molecular Oncology, EarlyView.
LCOR (Ligand‐dependent corepressor) mRNA encapsulated in polymeric nanoparticles restores LCOR activity in tumor cells, constraining aggressive tumor cell states and increasing tumor immunogenicity. This reprogramming makes tumor cells more vulnerable to T‐cell attack and enhances their response to immune‐checkpoint immunotherapy.
Gabriel Serra‐Mir, Elena Haro‐Martínez, Sandra Blasco‐Benito, Chiara Cannatà, José Ángel Palomeque, Anna López‐Plana, Maria Sanz‐Flores, Marc Sabartés, Cristina Fornaguera, Toni Celià‐Terrassa   +9 more
wiley   +1 more source

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery.

, 2023
Since the publication of the Society for Immunotherapy of Cancer's (SITC) original cancer immunotherapy biomarkers resource document, there have been remarkable breakthroughs in cancer immunotherapy, in particular the development and approval of immune ...
Maecker, Holden T, Kleen, Thomas O, Novosiadly, Ruslan D, Hu-Lieskovan, Siwen, Gupta, Sumati, Sims, Tasha, Lund, Amanda W, Mahnke, Yolanda D, Janetzki, Sylvia, Koguchi, Yoshinobu, Dhodapkar, Kavita, Hanks, Brent A, Grivel, Jean-Charles JB, Bhaumik, Srabani, Maccalli, Cristina, Zhao, Yingdong, Selvan, Senthamil R   +16 more
core   +1 more source

Attitudes of cancer patients toward ctDNA‐based liquid biopsy for follow‐up

Molecular Oncology, EarlyView.
This mixed‐methods study explored cancer patients' experiences, knowledge, and preferences regarding ctDNA‐based liquid biopsy for follow‐up. Awareness of ctDNA was low and recall of previous liquid biopsy was imperfect, yet acceptance was high.
Siddharth Chhajlani, Laura Mariën, Caro De Weerdt, Sanne Wouters, Laure‐Anne Teuwen, Hans Prenen, Katleen Janssens, Timon Vandamme   +7 more
wiley   +1 more source